Table 1.

Factors associated with statin utilisation, 2015–2020

	Exponentiated coefficient (CI)*
	High-income countries	Low/middle-income countries
No†	40	33
Health expenditure per capita ($)‡	1.01 (1.01 to 1.02)*	1.17 (1.12 to 1.22)*
OOP health expenditure (%)§	0.99 (0.91 to 1.09)	0.89 (0.82 to 0.96)*
IHD mortality rate¶	1.00 (0.99 to 1.02)	1.02 (1.01 to 1.03)*

*P<0.05.

*Statin utilisation is defined as defined daily doses per 1000 population >40 years per day. Here logged statin utilisation is examined. Data for 2020 are based on statin utilisation from January to September 2020.

†Countries in Central America and West Africa were excluded because IQVIA does not report country-specific information for these regions.

‡Increments of 100.

§Increments of 10.

¶Age-standardised IHD mortality rate, increments of 10.

IHD, ischaemic heart disease; No, number; OOP, out-of-pocket.